Article Text

Download PDFPDF
Anti-TNF-α for treatment of amyloidosis associated with Crohn’s disease
  1. A Fernández-Nebro1,
  2. I Ureña2,
  3. M V Irigoyen2,
  4. R García-Vicuña3
  1. 1Servicio de Reumatología, Pabellón “Hospital Civil”, Hospital Regional Universitario Carlos Haya, Málaga, Spain
  2. 2Servicio de Reumatología, Hospital Regional Universitario Carlos Haya, Málaga, Spain
  3. 3Servicio de Reumatología, Hospital Universitario La Princesa, Madrid, Spain
  1. Correspondence to:
    Dr A Fernández-Nebro
    Servicio de Reumatología, Pabellón “Hospital Civil”, Hospital Regional Universitario Carlos Haya, Plaza del Hospital Civil s/n, 29009 Málaga, Spain; afernandezn{at}

Statistics from

We wish to comment on the case reported by Iizuka and colleagues (Gut 2006;55:744–5) of a patient who experienced a reduction in creatine levels from 4 to 2 mg/dl after three weeks of treatment with infliximab for amyloidosis associated with Crohn’s disease. Unfortunately, no details were provided of other concomitant factors, such as volume depletion or drugs, which may have affected baseline creatinine levels and their later course, irrespective of amyloidosis, or of the results of proteinuria observed in 1992.

In our experience,1 anti-TNF-α therapy has a rapid effect on proteinuria but not on renal function. In our patients it took several months (the most rapid decrease was from 1.6 to 0.94 mg/dl in three months) for serum creatinine levels to decrease by (mean (SD) percentage since baseline) 8.5 (16.6)% (range −21.4 to 39.4) after 70 (44) weeks (range 2–120), and only 36% of patients experienced a 20% reduction or greater.

We should also like to comment on the choice of anti-TNF for the management of amyloidosis in patients with quiescent Crohn’s disease but active spondyloarthropathy.

One of our patients was diagnosed by clinical, endoscopic, and histological criteria with spondyloarthropathy associated with Crohn’s disease …

View Full Text


  • Conflict of interest: None declared.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles